JP2020523348A5 - - Google Patents

Download PDF

Info

Publication number
JP2020523348A5
JP2020523348A5 JP2019568372A JP2019568372A JP2020523348A5 JP 2020523348 A5 JP2020523348 A5 JP 2020523348A5 JP 2019568372 A JP2019568372 A JP 2019568372A JP 2019568372 A JP2019568372 A JP 2019568372A JP 2020523348 A5 JP2020523348 A5 JP 2020523348A5
Authority
JP
Japan
Prior art keywords
compound
alkyl
cancer
salt according
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019568372A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523348A (ja
JP6979595B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/037221 external-priority patent/WO2018231910A1/en
Publication of JP2020523348A publication Critical patent/JP2020523348A/ja
Publication of JP2020523348A5 publication Critical patent/JP2020523348A5/ja
Application granted granted Critical
Publication of JP6979595B2 publication Critical patent/JP6979595B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019568372A 2017-06-13 2018-06-13 プロテインキナーゼ阻害剤としてのアミノチアゾール化合物 Active JP6979595B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762518855P 2017-06-13 2017-06-13
US62/518,855 2017-06-13
PCT/US2018/037221 WO2018231910A1 (en) 2017-06-13 2018-06-13 Aminothiazole compounds as protein kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2020523348A JP2020523348A (ja) 2020-08-06
JP2020523348A5 true JP2020523348A5 (enExample) 2021-07-26
JP6979595B2 JP6979595B2 (ja) 2021-12-15

Family

ID=64562741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019568372A Active JP6979595B2 (ja) 2017-06-13 2018-06-13 プロテインキナーゼ阻害剤としてのアミノチアゾール化合物

Country Status (13)

Country Link
US (1) US10300061B2 (enExample)
EP (1) EP3638237B1 (enExample)
JP (1) JP6979595B2 (enExample)
KR (1) KR102372288B1 (enExample)
CN (1) CN110831596B (enExample)
AU (1) AU2018284249B2 (enExample)
CA (1) CA3064081C (enExample)
ES (1) ES2949616T3 (enExample)
MX (1) MX393992B (enExample)
MY (1) MY201291A (enExample)
TW (1) TWI667236B (enExample)
WO (1) WO2018231910A1 (enExample)
ZA (1) ZA202000107B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102797697B1 (ko) 2018-05-25 2025-04-22 에이2에이 파마수티칼스, 잉크. 신종 항암제 후보로서, 매우 강력한 tacc3 억제제
EP4058447A4 (en) * 2019-11-14 2023-12-27 A2A Pharmaceuticals, Inc. ISOXAZOLE DERIVATIVES DIRECTED AGAINST TACC3 AS ANTICANCER AGENTS
WO2021178485A1 (en) * 2020-03-06 2021-09-10 National Health Research Institutes Pyrimidine compounds and their pharmaceutical uses
US11299489B1 (en) 2020-11-19 2022-04-12 National Health Research Institutes Thiazole compounds as protein kinase inhibitors
EP4323351A4 (en) * 2021-04-12 2025-07-30 A2A Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
JP2025509965A (ja) 2022-03-24 2025-04-11 エーツーエー ファーマシューティカルズ インコーポレーテッド がんを治療するための組成物及び方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003285007A1 (en) * 2002-10-30 2004-06-07 Merck & Co., Inc. Kinase inhibitors
CA2603826C (en) * 2005-04-04 2013-03-12 Ab Science Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
CA2610884A1 (en) 2005-06-09 2006-12-21 Merck & Co., Inc. Inhibitors of checkpoint kinases
GB0610909D0 (en) * 2006-06-05 2006-07-12 Merck Sharp & Dohme Therapeutic treatment
CN101534831B (zh) * 2006-09-11 2013-07-17 柯瑞斯公司 包含锌结合基团的取代的酪氨酸抑制剂
TW200906825A (en) * 2007-05-30 2009-02-16 Scripps Research Inst Inhibitors of protein kinases
US9255072B2 (en) * 2011-03-04 2016-02-09 National Health Rsearch Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
PH12014500168A1 (en) * 2011-07-27 2014-02-24 Ab Science Selective protein kinase inhibitors
WO2013143466A1 (zh) * 2012-03-27 2013-10-03 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代嘧啶衍生物
CN106279143A (zh) * 2015-05-11 2017-01-04 天津国际生物医药联合研究院 噻唑杂环类化合物及其制备方法和应用
WO2018106643A1 (en) * 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases

Similar Documents

Publication Publication Date Title
JP2020523348A5 (enExample)
JP2019511564A5 (enExample)
JP6495868B2 (ja) キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用
CN105163584B (zh) 用于治疗癌症的化合物
ES2779152T3 (es) Derivados de (2-(5-isoindolin-2-il)pirimidin-4-il)-amina como inhibidores de Rho-quinasa para tratar enfermedades autoinmunes
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
TWI594986B (zh) Antineoplastic agent effect enhancer
WO2020130125A1 (ja) 抗体-薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
ES2576497T3 (es) Compuesto de piperidina novedoso o sal del mismo
JP2019535746A5 (enExample)
JP2020503299A5 (enExample)
CA2519898A1 (en) Oral administration of cyclic protein tyrosine kinase inhibitors
JPWO2019191470A5 (enExample)
RU2016130932A (ru) Производные хинолона как ингибиторы рецептора фактора роста фибробластов
WO2018147275A1 (ja) 腫瘍治療用医薬組成物
JP2020536971A5 (enExample)
JP2005508953A5 (enExample)
RU2016137356A (ru) Соединение нафтиламида, способ его получения и применение
JP6883913B2 (ja) ヒストンデメチラーゼ阻害剤
JP2020534300A5 (enExample)
KR20220054695A (ko) 퀴나졸린 유도체
JPWO2021115426A5 (enExample)
JPWO2021007307A5 (enExample)
JPWO2019213570A5 (enExample)
TWI258481B (en) Hexacyclic compounds